A Research Study Combining the Study Drug VB-111 with Bevacizumab compared to Bevacizumab alone

What we are studying

This research study is a way of gaining new knowledge about GBM. If you decide to take part, you will be known as a “participant” rather than a “patient”. This research study is evaluating an investigational drug called VB-111 as a possible treatment for GBM. “Investigational” means that the drug VB-111 is still being studied and that research doctors are trying to find out more about it. It also means that the FDA (U.S. Food and Drug Administration) has not approved VB-111 for use in patients, including people with your type of cancer. It is expected that approximately 252 people will take part in this study; half will receive VB-111 together with bevacizumab and half will receive bevacizumab alone. Bevacizumab is currently approved by the FDA for treatment of recurrent GBM. It is anticipated that approximately 8 subjects will participate at this site.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Confirmed diagnosis of GBM
  • First or second progression of Glioblastoma
  • Life expectancy of at least 3 months
  • An interval of at least 12 weeks between prior radiotherapy or at least 23 days from prior chemotherapy
  • 42 days from nitrosoureas and enrollment in this protocol
  • Adequate organ function
  • Stable or decreasing dose of steroids if patient is receiving steroids
  • Ability to understand and willingness to sign a written informed consent document
  • Males and females of childbearing potential must utilize a standard contraception method throughout the course of the trial

What is involved

  • Physical exams
  • Ecgs
  • Mris
  • Blood work
  • Questionnaires
  • Study drug administration (VB-111 and Bevacizumab


Subjects will be reimbursed for mileage

Contact Information

Study Coordinator
Jill Weber Pfefferkorn
Principal Investigator
Glenn Lesser, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.